MedTrace Logo

Screening and Secondary Prevention Rheumatic Heart Disease Study

NCT05991219 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-08-15

No results posted yet for this study

Summary

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.

Conditions

  • Rheumatic Heart Disease

Sponsors & Collaborators

  • National Institute of Cardiovascular Diseases, Pakistan

    lead OTHER

Principal Investigators

  • Sabha Bhatti, MD · National Institute of Cardiovascular Diseases

Eligibility

Min Age
10 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05991219 on ClinicalTrials.gov